Most patients who present with patchy hair loss assume it is a complication of stress, a nutritional deficiency, or an early sign of pattern baldness. A meaningful proportion of these patients have alopecia areata, an autoimmune condition that is significantly more common in India than public awareness suggests and one that requires a completely different clinical approach from androgenetic alopecia.
Misidentifying alopecia areata as stress-related hair fall or early androgenetic alopecia has real clinical consequences. The wrong treatment does nothing. The correct treatment, when started early, can produce complete regrowth in the majority of cases. And in patients where alopecia areata is incorrectly assessed as a transplant candidate, surgery in an active areata lesion produces graft failure rather than growth.
This blog explains what alopecia areata is, why it is more common in India than most patients realise, how it is clinically distinguished from other hair loss conditions, and what treatment the evidence supports.
If you have patchy or unusual hair loss that has not responded to the treatments you have tried, a clinical assessment at RECOMB gives you a specific diagnosis before any treatment decision is made.
Book a Hair Loss Diagnosis at RECOMB, Surat →
WhatsApp: +91 7624008000 | www.recombhair.com
What Alopecia Areata Actually Is
Alopecia areata is an autoimmune condition in which the body's immune system incorrectly identifies hair follicles as foreign tissue and mounts an inflammatory attack against them. This immune attack disrupts the follicle's normal growth cycle, causing it to enter a premature resting phase and stop producing hair.
The precise trigger for this immune misidentification is not fully understood. Genetic factors play a role. Environmental triggers including viral infections, psychological stress, and other autoimmune conditions are associated with onset or relapse. The condition is not caused by nutritional deficiency, DHT, or scalp hygiene, the explanations most commonly offered to patients in primary care settings.
Alopecia areata does not destroy the follicle permanently in most cases. The follicle structure remains intact beneath the scalp surface, which is why spontaneous regrowth occurs in many patients and why treatment that suppresses the immune attack can produce significant regrowth in follicles that have been inactive for months.
The clinical presentation is characteristically patchy. Hair loss occurs in discrete, well-defined circular or oval areas where the scalp is smooth, completely bald within the patch, and shows none of the stubble that characterises androgenetic alopecia. The patches can be solitary or multiple, can appear anywhere on the scalp including the beard and eyebrow areas, and can progress, stabilise, or spontaneously regrow unpredictably.
Why It Is More Common in India Than Most Patients Realise
Alopecia areata has a global prevalence of approximately two percent of the population across a lifetime. In India, several factors contribute to what appears to be a higher prevalence and a higher proportion of cases that are underdiagnosed or mismanaged.
Genetic factors are relevant. Alopecia areata has a familial component and is associated with specific HLA gene variants. Populations with certain genetic backgrounds have higher prevalence, and these variants are present in significant proportions of the Indian population.
The association with other autoimmune conditions amplifies its prevalence. Thyroid autoimmunity, specifically Hashimoto's thyroiditis, occurs commonly alongside alopecia areata. Given the high prevalence of thyroid dysfunction in Indian women discussed in the thyroid and hair loss blog, the co-occurrence of autoimmune thyroid disease and alopecia areata is clinically relevant in the Indian patient population.
Psychological stress is a well-documented trigger for onset and relapse of alopecia areata. The high levels of sustained psychological stress in urban India, as discussed in the Gujarat hair loss blog, create a population-level trigger environment that is significant in a condition with known stress-mediated immune dysregulation.
Underdiagnosis compounds the apparent gap between prevalence and public awareness. Many patients with alopecia areata in India are told they have stress-related hair fall and given iron supplements or a biotin recommendation. Without trichoscopy, the specific clinical signs that distinguish alopecia areata from other conditions are not identified, and the correct diagnosis is never made. These patients continue with ineffective treatment while the condition progresses.
How Alopecia Areata Is Distinguished From Other Conditions
Accurate diagnosis requires clinical examination and trichoscopy. The following features distinguish alopecia areata from androgenetic alopecia and telogen effluvium.
The pattern of loss in alopecia areata is patchy and non-patterned. It does not follow the Norwood or Ludwig distribution. Bald patches can appear anywhere on the scalp, can be isolated or multiple, and their boundaries are typically sharp and well-defined rather than gradual as in androgenetic alopecia.
The scalp surface within an active alopecia areata patch is completely smooth and bald, without the fine miniaturised hairs visible under trichoscopy in androgenetic alopecia. The patch feels smooth to the touch because the follicles, while intact beneath the surface, are not producing any shaft at all.
Exclamation mark hairs are a characteristic trichoscopic finding in active alopecia areata. These are short hairs that are narrower at the root end than at the tip, producing an exclamation mark shape under magnification. Their presence confirms active disease.
Black dots and yellow dots visible under trichoscopy at follicle openings are additional characteristic findings of active alopecia areata that distinguish it definitively from other conditions.
The pull test at the border of an active patch in alopecia areata is strongly positive, meaning multiple hairs extract easily from the periphery of the patch where the immune attack is actively progressing. This differs from the positive pull test of telogen effluvium, which produces positive results across the whole scalp rather than specifically at the patch border.
The Different Forms of Alopecia Areata
Alopecia areata presents in several forms that differ in extent and clinical behaviour.
Patchy alopecia areata is the most common form and the one most patients present with. One or more discrete patches of complete hair loss on the scalp, typically round or oval, with spontaneous regrowth occurring in many cases within six to twelve months.
Alopecia totalis refers to complete hair loss across the entire scalp. The immune attack has expanded beyond discrete patches to affect all scalp follicles. It is less common than patchy disease and has a more guarded prognosis for complete spontaneous regrowth.
Alopecia universalis is the most severe form, involving complete loss of all body hair including eyebrows, eyelashes, beard, and body hair alongside total scalp loss. It is the least common form and represents the most extensive immune involvement.
Ophiasis pattern alopecia areata describes a band of hair loss along the periphery of the scalp, following the hairline from the temples across the occiput. This pattern is associated with a higher risk of progression and poorer treatment response than patchy disease.
Understanding which form is present is important for setting realistic treatment expectations, because the prognosis for complete, sustained regrowth varies significantly between forms.
What Treatment the Evidence Supports
Treatment of alopecia areata aims to suppress the immune attack on the follicle and allow regrowth from structurally intact follicles that have not yet been permanently damaged.
Intralesional corticosteroid injection is the first-line treatment for patchy alopecia areata affecting less than 50 percent of the scalp. Triamcinolone acetonide injected directly into the affected patches suppresses local immune activity and stimulates regrowth in responding patients within six to eight weeks of the first session. Multiple sessions spaced four to six weeks apart are typically required. Regrowth rates for localised patchy disease with intralesional treatment are high, with the majority of patients showing meaningful regrowth in the treated areas.
Topical corticosteroids applied to the affected patches are used in patients who cannot tolerate injections, including children with patchy areata, and as maintenance treatment between injection sessions. Their response rate is lower than intralesional treatment but meaningful in early or small patches.
Topical minoxidil, while not specifically treating the autoimmune mechanism, can support regrowth alongside immunosuppressive treatment by prolonging the anagen phase in recovering follicles. It is used as an adjunct rather than a primary treatment in alopecia areata.
Systemic treatment is considered for extensive disease, rapidly progressing loss, or cases that have not responded to localised treatment. Options include systemic corticosteroids for short-term disease control and JAK inhibitors, a newer class of targeted immune modulators, which have produced significant regrowth in clinical trials for alopecia totalis and universalis and represent the most significant advance in alopecia areata treatment in the past decade.
Contact immunotherapy using diphenylcyclopropenone applied to the scalp to produce a controlled allergic reaction that redirects immune activity away from follicles is a specialised treatment used in extensive or refractory cases at dermatology centres.
Why Hair Transplant Is Not the Answer for Active Alopecia Areata
This is a critical clinical point that every patient with alopecia areata must understand.
Hair transplant surgery is contraindicated in active alopecia areata. Transplanting grafts into scalp affected by active immune attack produces graft failure rather than growth, because the same immune mechanism that is destroying native follicles will attack the transplanted grafts.
Even in patients with alopecia areata that appears to be in remission, the risk of relapse post-surgery is real. The surgical stress of a transplant procedure has been documented as a trigger for alopecia areata relapse, meaning surgery in a patient with a history of alopecia areata carries the risk of inducing a new episode of immune activity.
Hair transplant may be considered in very specific circumstances for patients with stable, confirmed alopecia areata in complete long-term remission, but only after careful clinical assessment that confirms remission duration and absence of active disease markers. This is not a routine clinical scenario and requires specialist evaluation.
Patients who have been quoted for a hair transplant without a diagnosis that specifically excludes active alopecia areata have not been adequately assessed. Trichoscopy is the tool that makes this distinction, and any surgical plan for patchy or atypical hair loss must include it.
RECOMB's Approach (2026)
At RECOMB Hair Transplant Centre, Surat, alopecia areata is specifically assessed for at every new patient consultation through trichoscopy. Dr. Krishna Bhalala's background as a DNB Dermatologist means that the clinical diagnosis, treatment, and monitoring of alopecia areata are handled within the same consultation rather than requiring referral out, allowing patients to receive a complete management plan in a single clinical relationship.
Patients presenting with patchy hair loss receive a trichoscopic examination that specifically looks for the characteristic features of active alopecia areata before any other treatment is discussed. A patient with active alopecia areata is never recommended a hair transplant until the condition is in confirmed remission and the clinical picture supports surgical candidacy.
For patients with alopecia areata, treatment planning is focused on suppressing the immune attack, supporting regrowth in affected zones, and monitoring for the progression or remission patterns that determine what additional treatment is needed and at what point.
Final Takeaway
Alopecia areata is more common in India than most patients or clinicians in general practice recognise. It is consistently underdiagnosed because it is mistaken for stress-related hair fall and managed with treatments that have no mechanism of action relevant to an autoimmune condition.
The correct diagnosis changes everything. A patient with alopecia areata who receives intralesional corticosteroid treatment has a high probability of significant regrowth. The same patient who is told to take iron supplements and reduce stress will wait months for an improvement that will not come.
Trichoscopy makes this diagnosis in most cases within a single examination. The absence of trichoscopy from a consultation that encounters patchy or atypical hair loss is a clinical gap with real consequences.
Dr. Krishna Bhalala and Dr. Nilesh Kachhadiya conduct a limited number of personal consultations each week at RECOMB, Surat. If you have patchy hair loss that has not been formally diagnosed or has not responded to the treatments you have been given, this is where an accurate diagnosis starts.
Get a Proper Diagnosis for Your Patchy Hair Loss at RECOMB →
WhatsApp: +91 7624008000
We respond within 24 hours, 6 days a week.
www.recombhair.com
Contact RECOMB Hair Transplant Centre
RECOMB Hair Transplant Centre
19, Ground Floor, Zenon Building, Opp. Unique Hospital, near Kiran Motors, Khatodara Wadi, Surat, Gujarat 395001
Phone: +91 7624008000
Website: www.recombhair.com
